Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Participants with any stable disease that are at risk for a venous or arterial thrombotic disorder * Neonates ≥ 34 weeks gestational or ≥ 37 weeks post conceptual age (corrected gestational age) to \<18 years of age * Gestational and post-conceptual age will only be taken into consideration for eligibility up to 6 months of age * Neonates: defined as newly born (within 4 weeks) * Participants with any functional CVAD (Central Venous Access Device) in the upper or lower venous system Exclusion Criteria: * Current or recent (within 3 months of study drug administration) gastrointestinal disease or gastrointestinal surgery that, in the opinion of the investigator and the BMS Medical Monitor, could impact the absorption of the study drug * Active bleeding or high risk of bleeding * Inability to tolerate oral medication or administration of oral medication via an enteral tube (nasogastric tube \[NG tube\] or gastronomy tube \[G-tube\])